4,901 trials
Colorectal Carcinoma
Primary: Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period — 1 participants
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Drug-related Adverse Events (AEs) or Any Serious AEs — 1; 1; 1; 2 participants
Chronic Hepatitis C Infection
Primary: Sustained Virologic Response At 12 Weeks (SVR12) — 50 percentage of participants
Malignant Solid Tumour
Primary: Number of Participants With Any (Serious and Non-Serious) Adverse Event Measured to Assess Safety and Tolerability. — 12 participants
Sinusitis
Primary: Patency of Treated Area — 95 percentage of ostia treated
Alzheimer's Disease · Dementia
Primary: Caregiver Strain — 5.95; 6.96 units on a scale — p=<0.0001
Hepatitis C
Primary: Area Under the Curve (AUC) (0-infinity) of Vaniprevir in Blood Plasma Following Single Dose Administration — 2.68; 1.48; 5.09; 1.64 µM.hr
Schizophrenia · Dual Diagnosis · Schizoaffective Disorder
Primary: fMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC). — .40; .33 Z score
Hepatitis C
Primary: Pharmacokinetic of Boceprevir in the Presence of Ucalm (St John's Wort) — 4588; 4204; 11.6; 14.3 ng*h/mL
Pulmonary Nodule
Primary: Feasibility of Ultra Short-term Steroid Therapy to Increase the Accuracy of FDG-PET/CT Imaging — 3.97; 4.27 gm/ml
HIV
Primary: Maximum Observed Concentration (Cmax) of Raltegravir and Amlodipine Without and With Co-administration of the Other Studied Drug. — 1178; 1866; 8.47; 8.49 ng/mL
Chronic Hepatitis C
Primary: Number of Participants From Whom Detectable Concentrations of Hepatic Vaniprevir Are Obtained by FNA — 10; 9; 10 Participants
Healthy Volunteer
Primary: Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid — 100 ng/mL
Congenital Bleeding Disorder · Healthy
Primary: Safety (Physical Examination, Vital Signs, ECG, Haematology, Biochemistry, Urinalysis, Coagulation Factors, Coagulation-related Parameters, Injection Site Tolerability…
Major Depressive Disorder
Primary: Number of Dose Limiting Toxicity of Physical Examination — 0; 0 participants